Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

Also called NCT01135992

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 143 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01135992
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01135992. Non-randomized; no masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2016-01-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
Acronym
BEGIN™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01135992
Content hash
6d9600a1bfd13b8c654b4fcb86ba958b1f9542e5129458b9abff062c7e0c34a3